Participate in Research
Clinical trials help find new methods for diagnosing, treating, managing and preventing Crohn's disease and ulcerative colitis, the two main forms of inflammatory bowel disease. Even the most promising scientific findings must first be proven to be safe and effective in clinical trials before they can be used as standard treatment.
Talk to your doctor to find a clinical trial that might be suitable for you or someone you care about.
For more information about clinical trials, visit _
Clinical studies needing patient participants:
Other clinical studies:
IMPACT-IBD: Improving Outcomes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease (IBD)
Age of recruitment: 17 years and older
Person of Contact: Natasha Bollegala, Phone Number: 6473905970, Email:
Research in Interactions with the Healthcare System
Participants needed: Those with chronic conditions that have utilized the Canadian medical system
Person of Contact: Andreea Tamaian, Department of Psychology, University of Regina, email:
Physical Activity & IBD
Understanding the relationships between physical activity and resilience on quality of life in patients with inflammatory bowel disease in comparison to those without. The study involves a 10-15 minute survey () looking at physical activity, resilience levels, and quality of life.
Study Eligibility: Any person with inflammatory bowel disease who is able to read in English.
Person of Contact: Katie Taylor; Email: ; Phone+1 (208) 885-2007
Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis
A randomized trial of antimicrobials versus placebo in addition to fecal microbiota transplantation for the induction of remission in patients with active ulcerative colitis.
Site Investigators: Dr. Paul Moayyedi and Dr. Christine Lee
Person of Contact: Melanie Wolfe (Research Coordinator); Email: ; Phone: 905-521-2100 x 73601
“The Pedi FETCh Research Trial: Pediatric Fecal Transplant for Ulcerative Colitis”
The Pedi FETCh Research Trial (Pediatric Fecal Transplant for Ulcerative Colitis) is the first pediatric fecal transplant study for inflammatory bowel disease in Canada, and will be the first randomized controlled trial of fecal transplant in pediatric inflammatory bowel disease in the world. The trial is being lead by Dr. Nikhil Pai, and supported by the Division of Pediatric Gastroenterology and Nutrition at McMaster Children’s Hospital. Study collaborators include Dr. Christine Lee (Division of Infectious Disease at St. Joseph’s Hospital in Hamilton), and Paul Moayyedi (Division of Adult Gastroenterology at McMaster University), with support from the Farncombe Digestive Disease Research Institute at McMaster University.
Site Investigators: Dr. N. Pai
Person of Contact: Jelena Popov (Research Coordinator); Email: / Dr. Nikhil Pai Email: ; Phone: 905.521.2100 ext. 75637
More information, including eligibility, safety monitoring and frequently asked questions, is available on the website: .
“Denosumab, a monoclonal antibody to receptor activator of nuclear factor-Kappa B ligand (RANKL), in Crohn’s disease”
Site Investigators: Dr. John K. Marshall
Person of Contact: Gail Cappelli (905-521-2100 Ext 76986) or Mitzi Lawrence (905-521-2100 Ext 20601)
Project ARCC (Accelerating Research in Crohn’s and Colitis) – Developing new tools for IBD research
A study looking for individuals to give valuable feedback on from people who experience loose bowel movements in order to improve products to facilitate research and diagnostics.
Eligibility criteria: Adults suffering from Crohn’s disease, ulcerative colitis, inflammatory bowel disease (IBD) or Irritable Bowel Syndrome (IBS) who are experiencing loose bowel movements.
Compensation for complete participation. for more information.
If you are interested in participating, contact 1-866-813-6354 ext 326 or firstname.lastname@example.org
Study the effect of migration on chronic inflammatory diseases in South Asian Canadians
South Asian adults receive $25 cash for participating in a University of Toronto research study
Researchers at the University of Toronto are recruiting two types of participants to study the effect of migration on chronic inflammatory diseases, including Inflammatory Bowel Disease (IBD), in South Asian Canadian communities in the Greater Toronto Area (GTA), Canada.
Eligible participants would receive $25 (cash) compensation for participating in a 1-hour interview to share their thoughts and opinions on chronic inflammatory diseases and access to health care services. Participants can choose the location in GTA, Canada for the interview that is most comfortable and convenient for them.
PARTICIPANT TYPE 1
- 18-29 years of age
- South Asian* descent
- Born in Canada to a parent born in South Asia
- Have been diagnosed with any chronic inflammatory diseases**, including IBD
PARTICIPANT TYPE 2
- Any age
- South Asian* descent
- Born in South Asia
- A PARENT with a CHILD of any age, who was born in Canada and has been diagnosed with any chronic inflammatory diseases**, including IBD
*South Asian countries include: Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka
**Chronic inflammatory diseases include: Inflammatory bowel disease (IBD), asthma, celiac disease, Crohn’s disease, inflammatory bowel disease, lupus, multiple sclerosis, psoriasis, Takayasu's arteritis (& other types of arthritis), tuberculosis, type 1 diabetes, etc.
Person of contact: Jessica Carlos, Project Manager, University of Toronto Mississauga
Phone: (647) 503-2706 | email: email@example.com
Additonal resources for clinical trials
Other Clinical studies needing patient participants:
You may also search for clinical trials through the following sites:
Clinical Trial Survey
Have you been asked to participate in a clinical trial? Researchers in Canada are seeking feedback on your experience with declining or participating in a clinical trial via an on-line, anonymous survey.
- To access this on-line survey, please click HERE
- More information about this survey can be found HERE
Crohn’s and Colitis Canada is an independent, voluntary health agency and does not approve, endorse or recommend any specific product or therapy but provides information to assist individuals in making their own decisions.